Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
preS-containing recombinant hepatitis B vaccine (Pichia pastoris)
- Development stage
- Unknown
- Lead developer
- Chengdu Institute of Biological Products
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A third-generation recombinant protein subunit vaccine developed by the Chengdu Institute of Biological Products for the prevention of hepatitis B virus (HBV) infection. The vaccine is produced using the *Pichia pastoris* yeast expression system and is distinguished by the inclusion of the preS1 and preS2 regions of the HBV surface protein, in addition to the standard S antigen. This design is intended to enhance the vaccine's immunogenicity, particularly in individuals who are non-responsive or hypo-responsive to conventional second-generation vaccines that contain only the S antigen. By providing a broader range of epitopes, the vaccine aims to elicit a more potent and protective immune response against HBV.
- Other names
- Recombinant Hepatitis B Vaccine (Pichia pastoris) containing preS
02
Targets
pre-S2 (Hepatitis B virus pre-S2 region)preS1 (HBV presurface protein 1)
Beyond the preview
Go deeper on preS-containing recombinant hepatitis B vaccine (Pichia pastoris).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on preS-containing recombinant hepatitis B vaccine (Pichia pastoris).